Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
about
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsRadiotherapy and "new" drugs-new side effects?Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivoMembranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma.Minimizing the immunogenicity of antibodies for clinical application.Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II studyClinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5-year outcomes.Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma.Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinomaPredicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modellingEfficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinomaNimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Trial Watch: Monoclonal antibodies in cancer therapyRandomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancerImmunotherapy of malignant brain tumors.Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 TrialA pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.Epidermal growth factor inhibition in solid tumours.Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumabEGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its F(ab')(2) Fragment in an Immunocompetent Mouse ModelEnhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy.Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancerCetuximab in the treatment of head and neck cancer.
P2860
Q24645217-357368A7-B3B2-4341-AEE2-48239B4B84C0Q26750719-F360A64F-2210-4893-A1FE-B003D99FD1FEQ26861498-6F9EEEA4-1528-4E6D-A711-CF201204D318Q27853322-1599687C-2609-493B-A5F3-9818D0453923Q30430971-01FD6857-F26A-4B6C-B6C5-7CC1A970B0BBQ31150735-DC00428C-3EBA-464C-A1C0-A8A5FC561757Q33779303-3023CB59-219C-4DD9-857D-246D30B49031Q33994022-FEB3E4D1-093E-4E25-97F2-B79AF7A8D9B2Q34223866-82C60E63-2506-48A5-B6D5-AE29154C8BFAQ34343043-04BE374A-0502-4BED-B013-14BE3F12C85CQ34586272-111BB2D6-7DD8-4EB9-A519-96E2568CF61CQ34618994-A2027E89-CFBB-4DF7-BA91-C27FFFD2523EQ34622206-7E606A4F-F65E-4AEE-8471-5788A27CFAE9Q35142705-6B53F433-543F-4C5B-98AD-A75FE0B61B53Q35534349-8DEDF517-C1B2-4940-9198-1611E67FA056Q35667892-B882BF69-0852-46CB-9B00-1C1D96D34CCEQ35905876-76CD6AD4-2DAD-4546-A6CF-3D544B96F38BQ35948006-7FCF8C87-E4FC-4DDF-B25F-DDFA7C94913DQ35955366-FF1DF464-5398-42EB-A05F-96206BB7391AQ35986801-4839439B-E99E-4C83-BE55-750800DF05BFQ36038408-190723CD-FF91-49EF-B3A9-DD231009FB86Q36065419-FFF40BBA-B50A-470A-8EC7-72E98EF70D92Q36162929-FE3A3755-05B6-444F-B08A-4C9D5BCF6687Q36175239-4B3E295B-34CF-4F3C-ADA8-1258CCD6B492Q36194219-51676C79-90EC-4424-9056-CDA2E93FFF8EQ36214463-82662CBD-6821-46CF-9450-803870490241Q36220797-9A9C52A4-00BE-4B09-868F-92641812E722Q36239648-865DEFF1-8BF0-4C32-BAE9-894606FDDF7FQ36285551-36CDD2A0-A9A5-4768-81E7-2075FA3E75E1Q36302347-E84CEC08-03AA-4D1A-88B7-F710673ABA24Q36303845-543D1669-6DBC-4E47-ABDE-9E914FD5C91EQ36307227-5CCC9439-21AA-44B3-9B96-FA3B12E2D7BAQ36371601-6185427C-F27C-4F14-AB52-20DC852246CAQ36440219-9F94E384-FC8B-49D9-86F6-98961F49A0B3Q36484536-2D2EA773-3A26-4DC0-AB43-078E9EFA390EQ36517741-766B32FE-25D9-4C07-9889-B910A65B14BAQ36588378-0DA65F53-BF9D-4BDD-B8E3-B69CCF60597FQ36613969-A408B174-0A9A-4DBF-9BDF-7E73E9CA967AQ36656070-DD212217-B674-43D4-A6AF-D32E0CA4DFB7Q36668224-BEB845AE-BD32-45A0-863B-0E07C6A3C63E
P2860
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Use of the humanized anti-epid ...... head and neck cancer patients.
@en
Use of the humanized anti-epid ...... head and neck cancer patients.
@nl
type
label
Use of the humanized anti-epid ...... head and neck cancer patients.
@en
Use of the humanized anti-epid ...... head and neck cancer patients.
@nl
prefLabel
Use of the humanized anti-epid ...... head and neck cancer patients.
@en
Use of the humanized anti-epid ...... head and neck cancer patients.
@nl
P2093
P921
P356
P1476
Use of the humanized anti-epid ...... head and neck cancer patients.
@en
P2093
Agustín Lage
Carlos Roca
Daniel Alvárez
Eduardo Fernández
Enrique Renginfo
Idrissa Leonard
James Koropatnick
Marta Osorio
Mayra Ramos
Normando Iznaga-Escobar
P304
P356
10.1200/JCO.2004.03.089
P407
P577
2004-05-01T00:00:00Z